Giuseppe
Emeritus
[Source: Eurosurveillance, full text: (LINK). Abstract, edited.]
Eurosurveillance, Volume 16, Issue 42, 20 October 2011
Surveillance and outbreak reports
The European gonococcal antimicrobial surveillance programme, 2009
M J Cole (
)<SUP>1</SUP>, M Unemo<SUP>2</SUP>, S Hoffmann<SUP>3</SUP>, S A Chisholm<SUP>1</SUP>, C A Ison<SUP>1</SUP>, M J van de Laar <SUP>4</SUP>
Citation style for this article: Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, van de Laar MJ. The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill. 2011;16(42)
ii=19995. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19995
Date of submission: 03 May 2011 <HR>Neisseria gonorrhoeae antimicrobial susceptibility is monitored in the European Union (EU) and the European Economic Area (EEA) by the European gonococcal antimicrobial surveillance programme (Euro-GASP). Results from 17 EU/EEA Member States in 2009 showed that 5% of isolates had decreased susceptibility to cefixime, an upward trend in the minimum inhibitory concentrations of ceftriaxone and a high prevalence of resistance to ciprofloxacin (63%) and azithromycin (13%). These results are of public health value and highlight the need for healthcare professionals to be aware of possible cefixime treatment failures. Euro-GASP is being implemented in additional EU/EEA Member States to achieve greater representativeness. In addition, Euro-GASP aims to set up a system which will allow biannual reporting of antimicrobial resistance in the EU/EEA, with a transition from centralised towards decentralised testing, and will link epidemiological data to laboratory data to enhance surveillance. The benefits of this approach include more timely detection of emerging trends in gonococcal resistance across the EU/EEA and the provision of a robust evidence base for informing national and European guidelines for therapy.
- -------
Eurosurveillance, Volume 16, Issue 42, 20 October 2011
Surveillance and outbreak reports
The European gonococcal antimicrobial surveillance programme, 2009
M J Cole (
- Health Protection Agency, London, United Kingdom
- ?rebro University Hospital, ?rebro, Sweden
- Statens Serum Institut, Copenhagen, Denmark
- European Centre for Disease Prevention and Control, Stockholm, Sweden
Citation style for this article: Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, van de Laar MJ. The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill. 2011;16(42)
ii=19995. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19995 Date of submission: 03 May 2011 <HR>Neisseria gonorrhoeae antimicrobial susceptibility is monitored in the European Union (EU) and the European Economic Area (EEA) by the European gonococcal antimicrobial surveillance programme (Euro-GASP). Results from 17 EU/EEA Member States in 2009 showed that 5% of isolates had decreased susceptibility to cefixime, an upward trend in the minimum inhibitory concentrations of ceftriaxone and a high prevalence of resistance to ciprofloxacin (63%) and azithromycin (13%). These results are of public health value and highlight the need for healthcare professionals to be aware of possible cefixime treatment failures. Euro-GASP is being implemented in additional EU/EEA Member States to achieve greater representativeness. In addition, Euro-GASP aims to set up a system which will allow biannual reporting of antimicrobial resistance in the EU/EEA, with a transition from centralised towards decentralised testing, and will link epidemiological data to laboratory data to enhance surveillance. The benefits of this approach include more timely detection of emerging trends in gonococcal resistance across the EU/EEA and the provision of a robust evidence base for informing national and European guidelines for therapy.